“There are several other discussions that we have been having with private equity investors who are interested in making an investment in Biocon Biologics and that will help us bring down the $1.2 billion debt … help us reduce the interest component that we see in the P&L,” Shreehas Tambe, chief executive officer and managing director of Biocon Biologics, said in an interview.

Leave a Reply

Your email address will not be published. Required fields are marked *

Generated by Feedzy